tbuckley/cabot-search huggingface dataset:
Genetic relatedness of Mycobacterium avium-intracellulare complex isolates from patients with pulmonary MAC disease and their residential soils
Authors: K. Fujita, Y. Ito, T. Hirai, K. Maekawa, S. Imai, S. Tatsumi, A. Niimi, Y. Iinuma, S. Ichiyama, M. Mishima
Journal: Clinical Microbiology and Infection (2012)

Mycobacterium avium-intracellulare complex (MAC) strains were recovered from 48.9% of residential soil samples (agricultural farms (n = 7), residential yards (n = 79), and planting pots (n = 49)) of 100 pulmonary MAC patients and 35 non-infected control patients. The frequency of MAC recovery did not differ among soil types or among patients regardless of the presence of pulmonary MAC disease, infecting MAC species or period of soil exposure. Variable numbers of tandem repeats (VNTR) analysis for MAC clinical and soil isolates revealed 78 different patterns in 47 M. avium clinical isolates and 41 soil isolates, and 53 different patterns in 18 M. intracellulare clinical isolates and 37 soil isolates. Six clinical and corresponding soil isolate pairs with an identical VNTR genotype were from case patients with high soil exposure (≥2 h per week, 37.5% (6/16) with high exposure compared with 0.0% (0/19) with low or no exposure, p <0.01), suggesting that residential soils are a likely source of pulmonary MAC infection.
Mechanisms of Bortezomib resistance in selected Bortezomib-resistant DLD1 cell line
Authors: Lidong Zhang, Fengqin Dong, Shuhong Wu, Xiaobo Cao, Charles Rodarte, Bingliang Fang, W. Roy Smythe
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

619 

Proteasome inhibitors have exhibited strong antitumor activity against a wide range of malignancies. Moreover, Bortezomib (PS-341), a specific proteasome inhibitor, has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma. However, a clinical phase II trial showed that only 35% of patients with relapsed refractory multiple myeloma responded to Bortezomib, but the other 65% of patients did not response to this agent, suggesting that resistance to proteasome inhibitors may impede clinical use of these agents. In this study, to characterize mechanisms of this resistance and further develop strategies to overcome it, we selected a Bortezomib-resistant cell line by repeated treatment of DLD1 cells with Bortezomib and name it DLD1-PS-341-R cells. DLD1 cells are very sensitive to Bortezomib and the cell viability were below 5 % 24 hours after treatment with 25 nM of Bortezomib, while DLD1-PS-341-R cells are quite resistant to Bortezomib and the cell viability were over 80 % 24 hours after treatment with 200 nM of Bortezomib. Compared with DLD1 cells, DLD1-PS-341-R cells did not show G2/M phase arrest and dramatic Bik accumulation after treatment with Bortezomib. Subsequent study showed that, despite the same concentration of treatment, DLD1-PS-341-R cells had lower intracellular concentrations of Bortezomib than DLD1 cells had. Our results suggest that lower intracellular concentrations of Bortezomib in DLD1-PS-341-R cells, rather than deregulation of Bortezomib-induced cell cycle and apoptosis signaling pathways, may account for Bortezomib resistance in DLD1-PS-341-R cells.
Abstract MP56: Misclassification of Incident Heart Failure Hospitalizations in Administrative Claims Data: The Atherosclerosis Risk in Communities (ARIC) Study.
Authors: Ricky Camplain, Anna Kucharska-Newton, Lloyd E Chambless, Jacqueline D Wright, Kenneth R Butler, Carmen Cuthbertson, Gerardo Heiss
Journal: Circulation (2015)

Background: Estimation of disease incidence from administrative data requires an adequate look-back (prevalence) period to exclude pre-existing conditions from the incidence risk set. We characterized optimal lengths of the prevalence period to minimize misclassification of incident heart failure (HF) hospitalization, a proxy for incident HF. Methods: Data for participants of the ARIC Study (a prospective longitudinal cohort of 15,792 individuals sampled from 4 US communities) were linked with CMS Medicare claims from the years 2000-2012. We included only participants with &gt;36 months of continuous CMS Medicare fee for service (FFS) enrollment. Each participant’s time-in-observation was divided into two phases. The first 36 months were the prevalence period. Observation time after an index date 36 months following the date of enrollment was the incidence period. HF hospitalizations were identified from CMS MedPAR records using ICD-9 code 428.xx in any position. Patients were classified as having a HF hospitalization in (a) both the prevalence and incidence periods, (b) in the prevalence period only, (c) in the incidence period only, or (d) neither. Incident HF was defined as the first HF hospitalization in the incidence period not preceded by a HF hospitalization in the prevalence period. The proportion of events misclassified as incident HF hospitalization was estimated from incremental reductions of the prevalence period to start 36, 30, 24, 18, 12, or 6 months before the index date. The impact of misclassification was estimated as differences in incidence per 1,000 patients at risk. Results: Of 11,054 ARIC participants enrolled in Medicare FFS, 9,568 met the study inclusion criteria. A total of 1,129 incident HF hospitalizations were identified based on the 36 month prevalence period, considered as the referent (incidence rate 118 HF hospitalizations per 1,000 patients at risk). Shortening the prevalence period to 24 months increased the HF incidence rate to 123 per 1,000, overestimating the number of incident HF hospitalizations by 4.2% while retaining over 90% of the sample. A 12 month prevalence period yielded an overestimation of the number of incident HF hospitalizations by 11% (incidence rate 129 per 1,000 patients at risk) while retaining 95% of the sample. Conclusions: Selection of too short of a prevalence period to define incident hospitalized HF from CMS Medicare claims data can introduce substantial misclassification. Consideration of several prevalence periods indicates that a 24 month prevalence period reduces the potential for bias in the estimation of incident hospitalized HF while retaining most observations.
The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα
Authors: P Vargas Romero, S Cialfi, R Palermo, C De Blasio, S Checquolo, D Bellavia, S Chiaretti, R Foà, A Amadori, A Gulino, G Zardo, C Talora, I Screpanti
Journal: Leukemia (2015)

The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα
Female pattern hair loss: beyond an androgenic aetiology? Reply from authors
Authors: P. Cousen, A. Messenger
Journal: British Journal of Dermatology (2010)

Journal Article Female pattern hair loss: beyond an androgenic aetiology? Reply from authors Get access P. Cousen, P. Cousen Department of Dermatology, Royal Hallamshire Hospital, Sheffield S10 2JF, U.K. Search for other works by this author on: Oxford Academic Google Scholar A. Messenger A. Messenger Department of Dermatology, Royal Hallamshire Hospital, Sheffield S10 2JF, U.K. Correspondence: Andrew Messenger. E‐mail: Andrew.Messenger@sth.nhs.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 5, 1 November 2010, Pages 1141–1142, https://doi.org/10.1111/j.1365-2133.2010.09956.x Published: 01 November 2010
Dermoscopy can be useful in differentiating scalp psoriasis from seborrhoeic dermatitis
Authors: G-W. Kim, H-J. Jung, H-C. Ko, M-B. Kim, W-J. Lee, S-J. Lee, D-W. Kim, B-S. Kim
Journal: British Journal of Dermatology (2010)

Psoriasis and seborrhoeic dermatitis are common erythematous-squamous dermatoses that may present with scaly erythematous patches on the scalp. Owing to the similar clinicopathological features of these dermatoses, their differentiation poses a diagnostic challenge, particularly when the lesions on the scalp are isolated.To evaluate the usefulness of dermoscopy in the clinical differentiation of scalp psoriasis and seborrhoeic dermatitis.This was a retrospective observational study to evaluate the characteristic dermoscopic features of scalp psoriasis and seborrhoeic dermatitis. The study included a total of 96 patients with lesions; these patients were recruited from two tertiary teaching hospitals in Korea (Pusan National University Hospital and Kyungpook National University Hospital). Among these, 55 patients had scalp psoriasis and 41 patients had seborrhoeic dermatitis.The most significant dermoscopic features of scalp psoriasis were red dots and globules, twisted red loops, and glomerular vessels. In contrast, seborrhoeic dermatitis was characterized by arborizing vessels and atypical red vessels with the absence of red dots and globules. Featureless areas devoid of any particular vascular patterns were also frequently observed in seborrhoeic dermatitis. Dermoscopic findings of red lines and other vascular patterns were not considered useful for differentiation because these were uncommon features in both diseases. Although scales were observed commonly in both diseases, there was no significant difference in the frequency and characteristics of the scales when they were observed using dermoscopy.Our study shows that the investigation of vascular patterns by using dermoscopy can be valuable for the clinical diagnosis and differentiation of scalp psoriasis and seborrhoeic dermatitis.
Guidelines of care for the management of psoriasis and psoriatic arthritis
Authors: Alan Menter, Neil J. Korman, Craig A. Elmets, Steven R. Feldman, Joel M. Gelfand, Kenneth B. Gordon, Alice Gottlieb, John Y.M. Koo, Mark Lebwohl, Craig L. Leonardi, Henry W. Lim, Abby S. Van Voorhees, Karl R. Beutner, Caitriona Ryan, Reva Bhushan
Journal: Journal of the American Academy of Dermatology (2011)
LEFT BUNDLE BRANCH BLOCK WITH SPONTANEOUS REMISSION AFTER AT LEAST THREE YEARS
Authors: S L MYRE, B F FULLER
Journal: Annals of Internal Medicine (1951)

Case Reports1 June 1951LEFT BUNDLE BRANCH BLOCK WITH SPONTANEOUS REMISSION AFTER AT LEAST THREE YEARSS. L. MYRE, M.D., B. F. FULLER, M.D.S. L. MYRE, M.D.Search for more papers by this author, B. F. FULLER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-34-6-1497 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is agreed that a bundle branch block, once established, remains as a permanent abnormality for the remainder of the patient's life. While there are numerous reports of cases of functional or transient heart blocks, we found only one report of a spontaneous remission of a bundle branch block once it was established for a period of a year or more.1CASE REPORTA 56 year old male was first seen on January 1, 1943. He had been in excellent health prior to this time, save for a mild upper respiratory infection of about a week's duration. On January 1,...Bibliography1. Kalett J: Bundle branch block with spontaneous remission after four years, Am. Heart J. 29: 120, 1945. CrossrefGoogle Scholar2. Yater WM: Pathogenesis of bundle branch block, Arch. Int. Med. 62: 1, 1938. CrossrefGoogle Scholar3. FreundSokolov HAR: Bundle branch block, Arch. Int. Med. 63: 318, 1939. CrossrefGoogle Scholar4. BestTaylor CHNB: The physiological basis of medical practice, ed. 4, Williams and Wilkins Co., Baltimore, 1945, p. 166. Google Scholar5. White PD: Heart disease, ed. 2, The Macmillan Co., New York, 1938. Google Scholar6. WilliusDryReeser FATJR: Life expectancy in conductive disturbances affecting the ventricular complex of the EKG, Arch. Int. Med. 67: 1008, 1941. CrossrefGoogle Scholar7. PfeifferLa Due HJS: Major surgical operations in the presence of bundle branch block, Am. J. M. Sc. 217: 369, 1949. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication June 7, 1949. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byReversion of bundle branch block with steroid therapyDie Rhythmusstörungen des Herzens (einschließlich der intramuralen Leitungsstörungen und des Alternans)Bilateral bundle branch blockCritical rates in ventricular conduction. IV 1 June 1951Volume 34, Issue 6Page: 1497-1501KeywordsHeartLeft bundle branch blockUpper respiratory tract infections ePublished: 1 December 2008 Issue Published: 1 June 1951 PDF downloadLoading ...
Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals
Authors: Marijn C. Meuwese, Erik S.G. Stroes, Stanley L. Hazen, Joram N. van Miert, Jan Albert Kuivenhoven, Robert G. Schaub, Nicholas J. Wareham, Robert Luben, John J.P. Kastelein, Kay-Tee Khaw, S. Matthijs Boekholdt
Journal: Journal of the American College of Cardiology (2007)
Abstract 14052: Mental Stress is Associated with More Transient Ischemic Dilatation of the Left Ventricle Than Physical Stress
Authors: Pratik M Pimple, Ernest V Garcia, Jonathon Nye, Ibhar Al Mheid, Kobina Wilmot, Ronnie Ramadan, Amit J Shah, Paolo Raggi, Fabio Esteves, Michael Kutner, Qi Long, J. Douglas Bremner, Arshed A Quyyumi, Viola Vaccarino
Journal: Circulation (2014)

Objective: Mental stress (MS) has been postulated to worsen coronary microvascular function. Mental stress-induced ischemia (MSI) predicts adverse events but does not correlate with CAD severity. Transient ischemic dilation (TID) detected with myocardial perfusion imaging is a measure of dilation in left ventricular cavity size with stress. However, TID may also reflect subendocardial hypoperfusion and impaired coronary flow reserve due to coronary microvascular disease. We addressed the hypotheses that MS is associated with larger TID as compared to physical stress (PS), and that patients with MSI have the largest TID.

Methods: 478 patients with CAD underwent 99mTc[[Unable to Display Character: ‐]]sestamibi myocardial perfusion imaging at rest and following both mental and physical (exercise/ pharmacological) stress testing. TID with each stress was calculated using Emory Cardiac Toolbox software. A 17-segments model was used to calculate summed stress scores to quantify perfusion defects with MS, PS, and at rest. TID with each stress condition and the difference between the two stress conditions were compared according to ischemia status.

Results: Ninety-three patients (19%) developed mental stress ischemia (MSI+), 131 (27%) developed physical stress ischemia (PSI+); 50 (10%) developed both MSI and PSI. Both MS and PS were associated with TID, but MS was associated with a larger increase in TID than PS (within-subject delta (δ) MS [[Unable to Display Character: –]] PS) = 0.02, p = 0.003). This difference was significantly larger in MSI+ patients (δMSI+ = 0.05, p = 0.002) than in MSI negative subjects (δMSI- = 0.01, p = 0.18). In contrast, PSI+ had a similar TID with PS and MS (δPSI+ = -0.003, p = 0.80). These results remained unaltered after adjustment by sociodemographic factors (age, sex, race, smoking status) and medical history (hypertension, hyperlipidemia and diabetes).

Conclusion: Mental stress is associated with TID, particularly in subjects who are MSI positive. TID may be a marker of subendocardial ischemia and coronary microvascular dysfunction in response to mental stress.
In brief
Authors: C Hicks
Journal: BMJ (2001)

A bid to break the current deadlock over plans to modernise the General Medical Council, the regulatory body for doctors in the United Kingdom, was made this week, with a radical new proposal for a reformed GMC comprising a single statutory body of 35 members.

The proposal, from the Joint Consultants Committee, was set out at the GMC's special consultative conference by Mr Jim Johnson, the committee's chairman. …
Comparing Long-Term Survival of Patients With Multivessel Coronary Disease After CABG or PCI
Authors: David J. Malenka, Bruce J. Leavitt, Michael J. Hearne, John F. Robb, Yvon R. Baribeau, Thomas J. Ryan, Robert E. Helm, Mirle A. Kellett, Harold L. Dauerman, Lawrence J. Dacey, M. Theodore Silver, Peter N. VerLee, Paul W. Weldner, Bruce D. Hettleman, Elaine M. Olmstead, Winthrop D. Piper, Gerald T. O’Connor
Journal: Circulation (2005)

Background— Randomized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous coronary interventions (PCIs) for patients with multivessel coronary disease (MVD) report similar long-term survival for CABG and PCI. These studies used a highly selected population of patients and providers, and their results may not be generalizable to actual care. Our goal in this study was to compare long-term survival of MVD patients treated with CABG vs PCI in contemporary practice. Methods and Results— From our northern New England registries of consecutive coronary revascularizations, we identified 10 198 CABG and 4295 PCI patients with MVD who may have been eligible for either procedure between 1994 and 2001. Vital status was obtained by linkage to the National Death Index. Proportional-hazards regression was used to calculate hazard ratios (HRs) for survival in CABG vs PCI patients after adjustment for comorbidities and disease characteristics. CABG patients were older; had more comorbidities, more 3-vessel disease, and lower ejection fractions; and were more completely revascularized. Adjusted long-term survival for patients with 3-vessel disease was better after CABG than PCI (HR, 0.60; P &lt;0.01) but not for patients with 2-vessel disease (HR, 0.98; P =0.77). The survival advantage of CABG for 3-vessel disease patients was present in all patient populations, including women, diabetics, and the elderly and in the era of high stent utilization. Conclusions— In contemporary practice, survival for patients with 3-vessel coronary disease is better after CABG than PCI, an observation that patients and physicians should carefully consider when deciding on a revascularization strategy.
Realizing the Benefits of Practical Clinical Trials
Authors: Joshua J Ofman, Deborah P Lubeck
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Deep Venous Thrombosis
Authors: John Spandorfer, Taki Galanis
Journal: Annals of Internal Medicine (2015)

This issue provides a clinical overview of deep venous thrombosis, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of science writers and physician writers. Editorial consultants from ACP Smart Medicine and MKSAP provide expert review of the content. Readers who are interested in these primary resources for more detail can consult http://smartmedicine.acponline.org, http://mksap.acponline.org, and other resources referenced in each issue of In the Clinic.
1063. In Utero β-Glucuronidase Gene Transfer with AAV Vectors Results in Widespread Transduction, Enzyme Activity, and Disease Correction in the MPS VII Mouse Brain
Authors: Brian A. Karolewski, John H. Wolfe
Journal: Molecular Therapy (2004)

Mucopolysaccharidosis (MPS) VII is a heritable lysosomal storage disease caused by the deficiency of b-glucuronidase (GUSB) enzyme. MPS VII is a chronic and progressive multiorgan disorder with signs of pathology already present during fetal life. Most therapeutic approaches for MPS VII have focused on postnatal treatments. Although these approaches can reverse storage lesions, the central nervous system (CNS) is more difficult to treat. We investigated in utero gene transfer in the MPS VII mouse CNS with AAV 1 and AAV2. We injected 1 μl of AAV1 (3.3×1013 genomes/ml) or AAV2 (1.4×1012 genomes/ml) into the lateral ventricle of the fetal brain on day 15.5 of gestation. AAV1 injected brains demonstrated extensive and widespread GUSB activity and mRNA expression the brain. There was retrograde transport of GUSB to the ganglion cells of the retina. GUSB activity was detected in the gray matter throughout most of the spinal cord segments. Storage lesions were reversed in the brain and spinal cord. Ubiquitin immunoreactivity was significantly reduced compared to the affected control. This suggested that in utero gene transfer with AAV1 corrected the disease and prevented the subsequent neurodegeneration. The AAV2 treated brains were treated with a lower dose of vector than the AAV1 experimental group, and these brains have significantly lower levels of enzyme and vector transduction. Very few GUSB positive ganglion cells were detected in the retina, and low levels of GUSB activity was present in the gray matter of the spinal cord. Evaluation of disease correction in the eye, spinal cord and brain for the AAV2 treated brains is ongoing. These results suggest that fetal gene therapy with AAV vectors may provide a therapeutic strategy capable widespread enzyme distribution and disease correction in the CNS.